Search Results 4861-4870 of 33128 for oral
Oral Cavity & Pharynx. 20.6 reported Mammogram in 2 years. Bladder. 15.1. 0.0. Leukemia. 12.5. 0.0. Target. 80.5%. Pancreas. Brain & ONS. Cervix. Esophagus.
Oral Cavity & Pharynx. 8.0. 2.8. Adults aged 50-75 years who reported. State. Cervix. 5.9. 0.0. Esophagus. 5.2. 6.6 being up-to-date with colorectal cancer ...
Oral Cavity & Pharynx. Uncategorized. 3.0. 1.9 being up-to-date with colorectal cancer screening. 0.8. 1.9. Target. 76.6%. 74.4%. 0.0. 0.0. Data Sources: ...
Oral Cavity & Pharynx. 1.4. 1.1. Target. 76.6%. 74.4%. Uncategorized. 0.0. 0.0. Data Sources: Incidence and Mortality from State Cancer Profiles (for FL, AZ, WI ...
The purpose of this study is to compare the assessment of the composition of the fecal, nasal,oral and skin microbiota in patients with AD (cases) as ...
Oral etoposide (up to 200 mg orally per day) may be given as an alternative ... Antileukemic therapy for the treatment of AML (excluding hydroxyurea or oral ...
PH requiring oral, IV, or inhaled therapy (such as epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, sildenafil, and tadalafil). 8. Increased ...
... Oral and throat cancer, Salivary gland cancer, Mouth cancer, Thyroid cancer, Head and neck cancer, Melanoma, Tonsil cancer, Skin cancer, Squamous cell ...
... years. Oral Cavity & Pharynx. 16.9. 2.8. Kidney & Renal Pelvis. Target. 80.5%. 15.3. 3.6. Pancreas. 14.0. 11.2. Ovary. 12.6. 6.1. Thyroid. 12.1. 0.4. County.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.